Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies
News updates: Subscribe
Unsubscribe


July 22, 2008
LCT Reports Clinical Benefits
July 17, 2008
LCT Hosts Seminar of World Leaders
July 14, 2008
LCT Quarterly Newsletter
July 11, 2008
Transcript of LCT interview with The Wall Street
June 26, 2008
LCT Informed of Progress for Diabetes Clinical Trial
 

News

LCT Reports Clinical Benefits
July 22, 2008
more

LCT Hosts Seminar of World Leaders
July 17, 2008
more

LCT Quarterly Newsletter
July 14, 2008
more

Transcript of LCT interview with The Wall Street
July 11, 2008
more

LCT Informed of Progress for Diabetes Clinical Trial
June 26, 2008
more

LCT Confirms Insulin Delivery from Implants
June 25, 2008
more

LCT Expands Diabetes Clinical Trial
June 5, 2008
more

LCT Lists on International OTCQX
June 3, 2008
more

LCT interviewed by New Zealand TV program, Close Up
May 21, 2008
more

LCT presents encapsulation technology at conference
May 12, 2008
more

LCT features on Channel Ten News
May 8, 2008
more

LCT prepares to list on international OTCQX
May 8, 2008
more

Appendi x4C - Quarterly results
April 30, 2008
more

LCT showcases proprietary nanotechnology
April 2, 2008
more

LCT announces compelling trial results
March 31, 2008
more

LCT receives US $6m in share capital
March 19, 2008
more

LCT is issued 4th US patent
March 17, 2008
more

General Meeting on Friday March 7, 2008 at 11am
March 3, 2008
more

LCT and US based Barbara Davis Center collaborate on clinical trial
February 27, 2008
more

LCT to present positive preliminary clinical results
February 13, 2008
more

Diabetes trial supported by US-based diabetes Foundation
February 12, 2008
more

Appendix 4C
LCT in strong cash position to accelerate clinical trial program

January 31, 2008
more

LCT features in Australian Investor magazine
January 30, 2008
more

LCT announces conversion by noteholders
January 25, 2008
more

LCT to receive US$6m
January 9, 2008
more

LCT Announces new US Director
January 8, 2008
more

LCT interview on Skybusiness News
December 6, 2007
more

LCT Receives A$6.0M in Capital Placement
November 30, 2007
more

LCT AGM Presentation
November 27, 2007
more

LCT Updates shareholders on Clinical Trial Progress at AGM
November 27, 2007
more

LCT to Cancel Rights At 20 cents
November 22, 2007
more

LCT recieves initial Navigroup funding
November 6, 2007
more

LCT announces further $6.4m capital placement
October 30, 2007
more

LCT presents at Rodman and Renshaw Healthcare conference
October 23, 2007
more

Further positive preliminary data on Diabecell trial
October 22, 2007
more

Positive preliminary data on DiabeCell phase I/IIa trial
October 9, 2007
more

LCT placement by international investors
October 3, 2007
more

Full Year Statutory Accounts
September 28, 2007
more

Receives Ethics Approval for Diabetes Clinical Trial
September 12, 2007
more

Preliminary final report for year end 30/6/2007
August 31, 2007
more

LCT to feature on ABC TV 7.30 report
August 29, 2007
more

LCT appoints Independent Director
August 23, 2007
more

Journal publishes durability of LCT biocapsule
August 1, 2007
more

Appendix 4C Quarterly report
July 31, 2007
more

LCT launches US ADR program
July 17, 2007
more

LCT receives $100k Enterprise Development Grant
July 05, 2007
more

LCT appoints The Channel Group to US Board
July 02, 2007
more

LCT successfully transplants first diabetes patient
June 14, 2007
more

Results of General Meeting
June 01, 2007
more

Another world-first for LCT's xeno facilities
May 22, 2007
more

The Living Cell Quarterly Newsletter
May 16, 2007
more

General Meeting Notice
May 2, 2007
more

LCT to present at Venture Forum, USA
May 1, 2007
more

Appendix 4C Quarterly Report
April 30, 2007
more

Regulatory review allows LCT clinical program to proceed
April 17, 2007
more

LCT to establish Level 1 American Depository Receipt Program
April 12, 2007
more

Pig cells help to fight diabetes TV3 NZ News Feature
April 2, 2007
link

LCT reports major step forward for islet transplantation
March 30, 2007
more

LCT Investor Update - March 2007
March 5, 2007
more

LCT Half Yearly Report Ended 31 Dec 2006
February 28, 2007
more

LCT closes successful SPP and placement raising $4.3 million
February 14, 2007
more

Australian Investor Online - LCT beginning clinical trials
February 9, 2007
more

Taylor Collison Limited Broker Report
February 5, 2007
more

LCT Quarterly Newsletter - The Living Cell
February 5, 2007
more

LCT announces underwriting of share purchase plan
February 2, 2007
more

Quarterly Cash Flow Report Period Ended 31 Dec 2006
Janaury 31, 2007
more

LCT to start clinical trial of Type 1 diabetes treatment
Janaury 30, 2007
more

LCT appoints CEO as Company Heads into New
Phase of Development

Janaury 24, 2007
more

LCT opens share purchase plan offer
Janaury 17, 2007
more

LCT announces share purchase plan
December 29, 2006
more

LCT Capital Raising Update
December 27, 2006
more

New Zealand Herald Article - Pig cell diabetes treatment
two steps away

December 20, 2006
more

LCT granted approval to manufacture xeno products for human use
December 19, 2006
more

New Zealand Herald Article - NZ pioneer brings cure for
diabetes a step closer

December 15, 2006
more

LCT investigates possible prevention of Type 1 diabetes
December 14, 2006
more

LCT Investor Update - December 2006
December 4, 2006
more

Progress on Funding Initiatives
November 24, 2006
more

AGM 2006 Results
November 24, 2006
more

AGM Presentation
November 24, 2006
more

LCT AusBiotech Presentation
November 20, 2006
more

General Meeting Resolutions
November 6, 2006
more

Invitation to the LCT Annual General Meeting
November 2, 2006
more

LCT Quarterly Newsletter - The Living Cell
November 1, 2006
more

Capital Raising Update & 4C Quarterly Cash Flow Report
October 31, 2006
more

Notice of Annual General Meeting & Proxy Form
October 25, 2006
more

LCT Annual Report
October 25, 2006
more

Financial Gateway to Asia - Research Report
October 20, 2006
more

LCT granted diabetes patent across the EU
October 19, 2006
more

Notice of General Meeting
October 5, 2006
more

LCT Investor Update - October 2006
October 2, 2006
more

Vacancy for Production Scientist
September 22, 2006
more

Preliminary Final Report (Appendix 4E) Period Ended 30 June 2006
September 13, 2006
more

LCT Investor Update - September 2006
September 4, 2006
more

New Zealand Herald Article - Pig cell treatment may start again
August 25, 2006
more

LCT announces new Chairman and additional independent director
August 25, 2006
more

LCT lodges application for clinical trial of its type 1
diabetes treatment

August 24, 2006
more

LCT to present at Royal Society of New Zealand meeting
August 15, 2006
more

The Living Cell - Quarterly Newsletter - August 2006
July 31, 2006
more

Quarterly Cash Flow Report Period Ended 30 June 2006
July 27, 2006
more

International journal highlights potential of LCT's cell implant treatment - Blackwell Publishing
July 25, 2006
more

Interview with LCT CEO Mr David Collinson
July 11, 2006
more

LCT raises $2.8m in fund transaction
July 7, 2006
more

LCT granted diabetes patent in the US
July 5, 2006
more

LCT Investor Update - July 2006
July 4, 2006
more

LCT Investor Update - Jun 2006
June 8, 2006
more

Vacancies for Senior Scientists
May 18, 2006
more

The Living Cell Quarterly Newsletter May 2006
May 2, 2006
more

New Zealand Herald Article
May 1, 2006
more

Quarterly Cash Flow Report Period Ended 31 March 2006
April 28, 2006
more

LCT awarded NZ$2.7m investment through the Foundation for Research, Science & Technology
April 26, 2006
more

LCT Investor Update - Apr 2006
April 12, 2006
more

Half Yearly Report Period Ended 31 December 2005
March 16, 2006
more

LCT and The Bionic Ear Institute Announce Agreement to Improve Hearing Loss
March 7, 2006
more


LCT Investor Update - Mar 2006
March 6, 2006
more


LCT General Meeting Presentation
February 24, 2006
more


LCT appoints Charles Macek as independent Director to the Board
February 24, 2006
more


LCT's biocapsule reviewed in international journal Biomaterials
February 21, 2006
more


LCT reports positive meetings with FDA and MedSafe - preparing for cell therapy trials
February 16, 2006
more


The Living Cell - Quarterly Newsletter - February 2006
February 7, 2006
more


Appendix 4C - Quarterly Cash Flow Report Period Ended 31 December 2005
January 31, 2006
more


Media Release - Quarterly Cash Flow Report Period Ended 31 December 2005
January 31, 2006
The cash balance at the end of the quarter was $4,552,000 compared to $3,261,703 at the end of the quarter to 30 September 2005.

A placement of ordinary shares during the quarter boosted cash reserves by $2,656,102 resulting in $4,999,005 in total cash proceeds from issuing shares during the present financial year. more


Notice of General Meeting
January 23, 2006
The General Meeting of Living Cell Technologies Limited ACN 104 028 042 ("Company") will be held at 2.45pm Sydney time on Friday 24 February 2006 at the Country Embassy in the NSW Trade and Investment Centre, Level 44, Grosvenor Place, 225 George St, Sydney, New South Wales, Australia. more


LCT set to raise additional US and European capital
January 23, 2006
Following continued strong interest from US and European Institutional investors in its recent placement, Living Cell Technologies Ltd (ASX:LCT) will hold a General Meeting on 24th February 2006 to obtain shareholder approval for the issue of shares in a further placement to US and European investors. more


Appendix 3B - New Issue Announcement
January 11, 2006
Appendix 3B - New Issue Announcement more


LCT raises additional funds from US investors
January 11, 2006
Living Cell Technologies (ASX:LCT) announced today that it has confirmed the placement of an initial investment of $3 million through a placement of ordinary shares working with Hunter Capital International to US shareholders at a $0.205 per share. more


LCT Investor Update - Jan 2006
January 11, 2006
This monthly update is to help explain the current business and research activities undertaken by Living Cell Technologies and the implications for the progression of its lead products to market. more


Living Cell Technologies awarded $100,000 grant by Cure Kids New Zealand
December 22, 2005
Living Cell Technologies (ASX:LCT) today announced Cure Kids New Zealand had awarded the cell therapy company a NZ$100,000 grant to pursue its program of liver cell transplantation treatment of the inherited bleeding disorder, haemophilia. more


LCT awarded $480,000 grant by NZTE
December 21, 2005
New Zealand Trade & Enterprise (NZTE) today announced it had awarded a NZ$480,000 grant to Living Cell Technologies Ltd (ASX:LCT) to help progress the development of cell based therapeutic products. more


Cell therapy supported through Bioethics recommendation
December 14, 2005
Living Cell Technologies Limited welcomes the final recommendation by Toi te Taiao: the Bioethics Council, that xenotransplantation should be allowed to develop in New Zealand. The Bioethics Council report entitled 'The Cultural, Spiritual and Ethical Aspects of Animal-to-Human Transplantation' presents final recommendations to the New Zealand Minister for Environment after a year of public consultation and review. more


New Zealand Herald article
December 13, 2005
Using pig and other animal parts for human transplants moved a step closer today after the Government's biotech ethics advisor gave the green light. The Bioethics Council opened the way for transplants of animal tissue into humans to be resumed once the Government is satisfied with the disease risk and other medical issues involved. But it wants patients receiving animal parts to be registered, to declare their status at the border, and for any subsequent medical treatment to be recorded. Six New Zealanders would already qualify for such registration -- they were injected with pig islet cells in 1996 as part of a clinical trial of treatment for diabetes. more


Living Cell Technologies to meet with the US Food and Drug Administration (FDA)
December 8, 2005
Living Cell Technologies (ASX: LCT) will meet with the US Food and Drug Administration (FDA) on Friday 9th December to discuss requirements for initiation of the first human study of its NeurotrophinCell product. more


LCT Investor Update - Dec 2005
December 1, 2005
This monthly update is to help explain the current business and research activities undertaken by Living Cell Technologies and the implications for the progression of its lead products to market. more


LCT AGM told of strong progress in 2005
November 16, 2005
The Chairman of Living Cell Technologies (ASX:LCT), Mr Michael Yates, told today's Annual General Meeting that the company had made strong progress throughout the last 12 months and was now looking forward to securing approval for phase I clinical trials of its NeurotrophinCell product. more


LCT AGM Presentation
November 16, 2005
Presentation given by Mr Michael Yates (Chairman), Mr David Collinson (CEO) and Prof Bob Elliott (Medical Director). more


Appendix 4C - Quarterly Cash Flow Report
October 27, 2005
Appendix 4C - Quarterly Cash Flow Report more


The Living Cell - Quarterly Newsletter, November 2005
October 26, 2005
The Living Cell - Quarterly Newsletter, November 2005 more


LCT files Pre-IND Request Letter with FDA for its NeurotrophinCell Product
October 20, 2005
Living Cell Technologies Limited (ASX: LCT) today announced that it has filed a request for a Pre-IND Meeting with the FDA to seek guidance and feedback on the development program for its NeurotrophinCell product. more


LCT Annual Report
October 18, 2005
LCT Annual Report more


Notice of AGM & Proxy Form
October 18, 2005
Notice of AGM & Proxy Form more


Leading US Neuroscientist appointed Chief Scientific Officer of LCT BioPharma
October 12, 2005
Leading US Neuroscientist appointed Chief Scientific Officer of LCT BioPharma more


LCT and MultiCell Announce Joint Venture - Opening Pathway for Stem Cell Delivery
October 4, 2005
Living Cell Technologies Limited has entered into a joint venture with US-based adult stem cell company, MultiCell Technologies Inc, to develop therapeutic liver cell applications. more


LCT awarded Highly Commended at NZ Hi-Tech Awards
October 2, 2005
LCT awarded Highly Commended at NZ Hi-Tech Awards more


Taylor Collison Limited Broker Report
September 14, 2005
Taylor Collison Limited Broker Report more


LCT Preliminary Final Report & Full Year Accounts
September 13, 2005
LCT Preliminary Final Report & Full Year Accounts more


LCT named as finalist for the 2005 NZ Hi-Tech Awards
September 1, 2005
LCT named as finalist for the 2005 NZ Hi-Tech Awards more


Hunting Party Securities Research Report
Aug 29, 2005
Hunting Party Securities Research Report more


LCT raises $2.3 million in placement
Aug 9, 2005
LCT raises $2.3 million in placement more


The Living Cell - Quarterly Newsletter, August 2005
Aug 5, 2005
The Living Cell - Quarterly Newsletter, August 2005 more


Taylor Collison Limited Broker Report
Aug 5, 2005
Taylor Collison Limited Broker Reporte more


New Zealand Herald article
Aug 3, 2005
Pigs and seaweed give hope to Huntington's victims more


LCT announces pre-clinical results for treating Huntington's disease
Aug 2, 2005
LCT announces pre-clinical results for treating Huntington's disease more


HD NtCell briefing
Aug 2, 2005
HD NtCell briefing more


Appendix 4C - Quarterly Cash Flow Report
July 29, 2005
Appendix 4C more


Results of General Meeting
May 25, 2005
Results of General Meeting more


The Living Cell - Quarterly Newsletter, May 2005
April 26, 2005
The Living Cell - Quarterly Newsletter, May 2005 more


LCT reports nine-year survival of transplanted pig islet cells in a diabetic patient
April 6, 2005
LCT reports nine-year survival of transplanted pig islet cells in a diabetic patient more


LCT successfully completes preclinical diabetes trial
April 5, 2005
LCT successfully completes preclinical diabetes trial more


Appendix 3B
March 21, 2005
Appendix 3B more


Release from ASX Escrow
March 15, 2005
Release from ASX Escrow more


LCT appoints Paris Brooke as General Manager
March 10, 2005
LCT appoints Paris Brooke as General Manager more


LCT Bioethics submission
March 07, 2005
LCT Bioethics submission more


LCT Acquires US$90m of Developed Cell Therapy Products
March 03, 2005
LCT Acquires US$90m of Developed Cell Therapy Products more


Appendix 4D - Half yearly report
March 02, 2005
Appendix 4D - Half yearly report more


LCT achieves successful use of its DiaβCell product in preclinical diabetes trial
February 24, 2005
LCT achieves successful use of its DiaβCell product in preclinical diabetes trial more


Commitment Test Entity - Second Quarter Report
February 1, 2005
Appendix 4C Quarterly Cash Flow - December 2004 more


Appendix 3B - Exercise of Options
February 1, 2005
Appendix 3B - Exercise of Options more


Change of Company Secretary and registered address
February 1, 2005
Change of Company Secretary and registered address more


LCT Newsletter January 2005
January 18, 2005
- Investor highlights
- Safety of cells from pigs for the treatment of humans with diabetes confirmed
- LCT technology protects brains of an animal model of Huntington's disease. more


Release from voluntary escrow
December 24, 2004
In accordance with ASX listing rule 3.10A, LCT advises that 17,620,275 ordinary shares will be released from voluntary escrow. more


Message from the Chairman of LCT: Mr Michael Yates
December 15, 2004
Mr M Yates has agreed to take on the role of Executive Chairman of the Company more


Appendix 3B - Issue of Shares
December 03, 2004
Appendix 3B - Issue of Shares more


Notice of change of interests of substantial holder David Collinson
November 29, 2004
Notice of change of interests of substantial holder David Collinson more


Appendix 3Y - Change of Director's Interest Notice for David Collinson
November 29, 2004
Appendix 3Y - Change of Director's Interest Notice for David Collinson more


Appendix 3X - Initial Director's Interest Notice for Alfred Vasconcellos
November 22, 2004
Appendix 3X - Initial Director's Interest Notice for Alfred Vasconcellos more


Appendix 3Y - Change of Director's Interest Notice for Michael Yates
November 22, 2004
Appendix 3Y - Change of Director's Interest Notice for Michael Yates more


Appendix 3Y - Change of Director's Interest Notice for Simon OLoughlin
November 22, 2004
Appendix 3Y - Change of Director's Interest Notice for Simon OLoughlin more


Notice of change of interests of substantial holder K One W One/Foundation Services
November 22, 2004
Notice of change of interests of substantial holder K One W One/Foundation Services more


Appendix 3B - Conversion of Note
November 15, 2004
The placement of shares announced on 3 November, 2004 triggered the conversion of the outstanding C Class Note into 1,070,811 ordinary shares. more


Appendix 3B - Directors and Employees Option Plan
November 15, 2004
Options issued under LCT's Directors and Employees Option Plan as adopted at the company's AGM more


Long-term safety of transplanted pig cells to humans confirmed
November 4, 2004
Long-term safety of transplanted pig cells to humans confirmed more


Appendix 3B Exercise of Options
November 3, 2004
Appendix 3B Exercise of Options more


Appendix 3B Issue of options to Underwriter
November 3, 2004
Appendix 3B Issue of options to Underwriter more


Appendix 3B Placement of shares
November 3, 2004
Appendix 3B Placement of shares more


Confirmation details of Share Placement
November 3, 2004
Confirmation details of Share Placement more


Results of AGM
October 29, 2004
Results of AGM more


Change of address
October 29, 2004
Change of address and Company Secretary more


First Quarter Activities Report
October 29, 2004
Appendix 4C First Quarter Activities Report more


Chairman's Address
October 28, 2004
Chairman's Address for Annual General Meeting more


LCT completes treatment phase of their pre-clinical study to treat diabetes
October 27, 2004
LCT completes treatment phase of their pre-clinical study to treat diabetes more


LCT treatment protects the brain from damage by Huntington’s disease
October 22, 2004
LCT treatment protects the brain from damage by Huntington’s disease more


Share Placement to extend R & D
October 12, 2004
Share Placement to extend R & D including Huntington's disease more


Appendix 3B, Release of securities from escrow
October 11, 2004
200,000 ordinary shares released from escrow on 1st October, 2004 more


Notice of AGM
September 27, 2004
Notice of Annual General Meeting and Proxy Form more


Expiration of Restriction Agreement
September 20, 2004
Expiration of Restriction Agreement for Bach Pty Ltd more


Notice of initial substantial holder
September 20, 2004
Notice of initial substantial holder more


Taylor Collison Limited Broker Report
September 16, 2004
Buy recommendation at 31.5 cents more


Xenotransplantation of neonatal porcine liver cells
September 10, 2004
Abstract presneted at the 20th International Congress of the Transplantation Society, Vienna more


Safety and efficacy of encapsulated islet xenotransplantation
September 10, 2004
Poster Abstract from the 20th International Congress of the Transplantation Society, Vienna more


LCT diabetes treatment successful in pre-clinical trials

September 7, 2004
LCT diabetes treatment successful in pre-clinical trials more


LCT report successful liver cell implantation
September 7, 2004
LCT scientists report successful cell implantation at international meeting: potential therapeutic use in humans to treat haemophilia more


Change of Director's Interest Notice
September 7, 2004
Change of Director's Interest Notice more


Initial Directors Interest
September 6, 2004
Statement of Initial Directors' Interests more


LCT lists on the ASX
September 1, 2004
Media Release - Warm welcome to ASX for new biotech LCT more


LCT closes successful IPO
August 26, 2004
LCT raises $6.36 mill. Trading is suspended on NSX to allow an orderly transfer to the ASX on 1 Sept 2004 more


LCT Preliminary Final Report
August 26, 2004
Living Cell Technologies Ltd Preliminary Final Report for the period 17 March, 2003 to 30 June, 2004. more


Supplementary Prospectus issued, interim stop order revoked.
July 20, 2004
LCT issues a Supplementary Prospectus, interim stop order revoked, Offer closes 12 August 2004. more


ASIC places interim stop order on LCT prospectus
July 5, 2004
ASIC issues interim order in relation to Living Cell Technologies Prospectus more


Results of General Meeting
June 29, 2004
Results of LCT General Meeting more


LCT Extends Offer
June 25, 2004
Living Cell Technologies extends offer period to 7 July more


Human diabetes trial in Italy lends strong support for LCT technology
June 7, 2004
Scientific Announcement more


Notice of Extraordinary General Meeting on 29 June 2004

May 26, 2004
Announcement more


LCT lodges prospectus
May 14, 2004
Announcement more


Scientific Announcement
May 6, 2004
Announcement more


Chairman Announced
April 7, 2004
Living Cell Technologies attracts international business leader more

LCT - Living Cell Technologies
What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors.
>more
   
graphic design and website design - PDF Communications Ltd